For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Echinacea purpurea Polysaccharide Reduces the Latency Rate in Herpes Simplex Virus Type-1 InfectionsGhaemi A.a, b · Soleimanjahi H.d · Gill P.c · Arefian E.d · Soudi S.e · Hassan Z.e
aFaculty of Medicine, Golestan University of Medical Sciences and Health Care, Gorgan, bYoung Researchers’ Club, Tehran Science and Research Campus, IAU, cDepartment of Nanobiotechnology, Faculty of Basic Sciences, and Departments of dVirology and eImmunology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran Corresponding Author
Amir Ghaemi, Hoorieh Soleimanjahi
Department of Virology, School of Medical Sciences, Tarbiat Modares University
P.O. Box 14115-111, Tehran (Iran)
Tel. +98 21 8801 3561, Fax +98 21 8801 3030
E-Mail email@example.com or firstname.lastname@example.org
Objective: During the latency period of herpes simplex virus type-1 (HSV-1), the virus can occasionally reactivate, travel back to the eye and cause recurrent ocular disease. As this condition arises from the ability of HSV-1 to produce a dormant infection, effective medication to prevent the virus enter a latent state should prevent it. In this study, we applied Echinacea polysaccharide (EP) fraction as prophylactic mediator for latency prevention. Methods: In order to investigate the protective properties of EP, we evaluated its immunostimulatory functions on different immune aspects that play important roles in latency prevention (particularly IFN-γ as one of the main indicators of cellular immunity and latency). Finally, we assessed establishment of latency by detection of thymidine kinase gene in trigeminal ganglia of BALB/c mice. Results: We demonstrated that EP promotes immune response, leading to a reduced latency rate, and it has a promising effect on latency prevention. Conclusion: EP was able to exert an antiviral action on the development of recurrent HSV-1 disease when supplied prior to infection.
© 2009 S. Karger AG, Basel